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Objectives: Both generic and disease-specific measures can be a useful strat-
egy for assessing HRQoL outcomes. This post-hoc analysis evaluated the ability 
of the generic EQ-5D-3L instrument and the OAB-5D disease-specific instrument, 
to assess changes in men with LUTS/BPH who have moderate-to-severe storage 
symptoms and voiding symptoms treated with fixed-dose combination (FDC) of 
solifenacin 6mg + oral controlled absorption system [OCAS™] formulation of tamsu-
losin (TOCAS, 0.4mg), TOCAS monotherapy, or placebo. MethOds: Data were avail-
able from a 12-week clinical trial (NEPTUNE). Patients completed the OAB-5D and 
EQ-5D-3L (including EQ-VAS) instruments. Analyses controlled for relevant patient 
characteristics. Analysis of covariance estimated and compared changes from base-
line at each time point for EQ-5D-3L, EQ-VAS and OAB-5D. Results: Statistically 
significant differences were seen in OAB-5D utilities with TOCAS monotherapy and 
FDC solifenacin 6mg + TOCAS compared with placebo after 4, 8 and 12 weeks in 
the overall population. When patients reporting full-health on EQ-5D-3L at baseline 
were excluded from the analysis to reduce the ceiling effect, the improvement 
from baseline (Δ 0.101 for FDC solifenacin + TOCAS) with EQ-5D-3L was 1.5 fold 
greater than the minimally important difference of 0.074. cOnclusiOns: This 
analysis indicates EQ-5D-3L captures several improvements in HRQoL resulting 
from treatment of LUTS/BPH with FDC solifenacin 6mg + TOCAS. However, OAB-5D 
shows larger and more consistent statistically significant differences between pla-
cebo and the treatment arms, and could be considered an appropriate alternative 
to EQ-5D utilities in health economic modelling.
total of 32 studies met inclusion criteria. Among the studies, 78.1% used a cross-
sectional design, 66.7% used both self reports and parent-proxy reports, and 43.3% 
used the Pediatric Quality of Life Inventory (PedsQL) 4.0 instrument. Eleven generic 
and two disease-specific instruments were used. The mean Efficace score for studies 
(N= 30) that measured or reported HRQoL outcomes was 8.9±1.3 (maximum = 11), 
which suggests overall high-quality data. Neither of the disease-specific instru-
ments has been fully validated; however, internal consistency, content validity, and 
hypotheses testing for the PedsQL 3.0 ESRD module were rated as good based on 
the COSMIN checklist. cOnclusiOns: Improved life expectancy in children and 
adolescents with CKD has led to increased concern about their HRQoL; however, 
few studies have used well-validated, disease-specific instruments. Future research 
is warranted to develop and further validate disease-specific HRQoL instruments 
for this population.
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